FMSFresenius Medical Care AG
Price
-13%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, growing in the filings, the market undecided.
Fresenius Medical Care is the world’s leading provider of products and services for individuals with kidney diseases based on publicly reported revenue. As a vertically integrated medical technology (MedTech) and healthcare service company, Fresenius Medical Care combines medical device engineering and manufacturing expertise with comprehensive patient care. The incidence of kidney disease is increasing worldwide. A significant rise in the drivers of kidney disease, such as obesity, diabetes, and hypertension, has elevated it to a global public health epidemic.
In the company’s own words · 20-F filed Feb 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Fresenius Medical Care AG (FMS) reported revenue of €5.07B in Q4 2025 (quarter ended Dec 31, 2025), down 0.3% from the same quarter a year earlier. That came with a gross margin of 27% and net income of €327M (6.5% of revenue). For the full year FY2025, revenue was €19.6B (+1.5% year on year) and net income €978M.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.